Methylphenidate - referral

Current status

European Commission final decision

Overview

The European Medicines Agency (EMEA) has completed a review of the safety of medicines containing methylphenidate. The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of these medicines continue to outweigh their risks when used to treat children aged six years and above and adolescents with attention deficit/hyperactivity disorder (ADHD). However, the Committee has concluded that the prescribing information for these medicines should be made consistent, in order to maximise their safe use across the European Union (EU). The review was carried out under an 'Article 31' referral¹.

¹ Article 31 of Directive 2001/83/EC as amended, referral under Community interest.

What is methylphenidate?

Methylphenidate is a medicine that is used to treat children aged six years and over and adolescents who have ADHD. It belongs to a group of medicines called 'psychostimulants'. Methylphenidate has been available since the 1950s, and has become widely used for ADHD since the 1990s. It is available in all EU Member States as various trade names including Ritalin, Concerta, Equasym, Medikinet and Rubifen. It is available as 'immediate-release' tablets and capsules that release methylphenidate straight away, and as 'modified-release' tablets that work over a few hours.

What is ADHD?

ADHD is a condition in which children show a persistent inability to concentrate, hyperactivity and impulsive behaviour, and which can lead to psychological, emotional, social and educational problems.

Methylphenidate-containing medicines can be used to treat ADHD as part of a comprehensive treatment programme that includes psychological, educational and social interventions. These interventions may be focussed on the child, parents or teachers, and range from giving information and advice, to formal psychotherapy. Methylphenidate should only be prescribed under the supervision of a specialist in childhood behavioural disorders when other methods have not been successful in changing behaviour.

In ADHD, methylphenidate is thought to increase the levels of the neurotransmitters noradrenaline and dopamine in the spaces between nerve cells in some areas of the brain, enhancing activity in areas of the brain that control attention, the ability to focus, concentration and impulsive behaviours.

Why were methylphenidate-containing medicines reviewed?

Over the past few years, concerns have been raised over the safety of methylphenidate, particularly over the possible risk of cardiovascular disorders (problems affecting the heart and blood vessels) and cerebrovascular disorders (problems affecting the blood vessels in the brain). Consequently, the European Commission asked the CHMP to carry out a full assessment of the benefit-risk balance of methylphenidate-containing medicines and to issue an opinion on whether the marketing authorisations for medicines containing methylphenidate should be maintained, varied, suspended or withdrawn across the EU.

Which data has the CHMP reviewed?

The CHMP has reviewed all of the available information on the safety of methylphenidate-containing medicines. This information came from studies carried out in experimental models and in humans, as well as information on side effects reported by doctors and patients since the medicines have been available on the market. The Committee also considered guidelines on the treatment of ADHD and on the screening and monitoring of patients before and during treatment.

The review focussed on cardiovascular safety (including increased blood pressure and heart rate, and disruption of the heart rhythm) and cerebrovascular safety (including stroke and migraine). In addition, the review looked at whether there is any evidence for a link between methylphenidate and psychiatric (mental) problems, reduced growth and sexual maturation. It also looked at information on the long-term effects of treatment.

What are the conclusions of the CHMP?

The Committee concluded that there was no need for an urgent restriction to the use of methylphenidate-containing medicines and that the benefits of methylphenidate-containing medicines continue to outweigh their risks, when they are used in their approved indication for children aged six years or over and adolescents with ADHD, as part of comprehensive treatment programmes. However, it concluded that new recommendations on prescribing the medicines and on pre-treatment screening and ongoing monitoring of patients are needed to maximise the safe use of these medicines.

Because the information provided to doctors on the safety of methylphenidate is not consistent across the EU, the Committee concluded that the product information of all methylphenidate-containing medicines authorised in the Member States should contain the following information:

• before treatment, all patients should be screened to see if they have any problems with their blood pressure or heart rate. The family history of cardiovascular problems should also be checked. Any patients with these problems should not be treated without specialist evaluation;
• during treatment, blood pressure and heart rate should be monitored regularly. Any problems that develop should be investigated promptly;
• there is a lack of information on the long-term effects of methylphenidate. For patients who take methylphenidate for more than a year, doctors should interrupt treatment at least once a year to determine whether continued treatment with methylphenidate is necessary;
• the use of methylphenidate could cause or worsen some psychiatric disorders such as depression, suicidal thoughts, hostility, psychosis and mania. All patients should be carefully screened for these disorders before treatment and monitored regularly for psychiatric symptoms during treatment;
• the height and weight of patients treated with methylphenidate should be monitored during treatment.

The CHMP also recommended that 'risk management plans' be put in place to monitor the safety of methylphenidate-containing medicines and minimise any possible long-term risks of their use. The plans should include educational materials for doctors who will prescribe methylphenidate. The Committee also recommended that information from ongoing studies into the medicine's safety should be evaluated as soon as it becomes available, and that further studies should be carried out on the long-term effects of methylphenidate.

Elements recommended for inclusion in Summaries of Product Characteristics for methylphenidate-containing medicinal products authorised for the treatment of ADHD in children aged six years and above and adolescents.

What are the recommendations for patients and prescribers?

• Methylphenidate-containing medicines remain suitable for the treatment of children aged six years or over and adolescents with ADHD as part of comprehensive treatment programmes.
• These medicines should only be prescribed and used in accordance with the updated prescribing information.
• Patients, parents or guardians who have any questions should speak to their doctor or pharmacist.

Questions and answers on the review of medicines containing methylphenidate

AdoptedReference Number: EMEA/658285/2008

Key facts

About this medicine

• Approved name:
  Methylphenidate
• International non-proprietary name (INN) or common name:
  methylphenidate

About this procedure

• Current status:
  European Commission final decision
• Reference number:
  EMEA/658285/2008
• Type:
  Article 31 referrals

  This type of referral is triggered when the interest of the Union is involved, following concerns relating to the quality, safety or efficacy of a medicine or a class of medicines.

Key dates and outcomes

• CHMP opinion date:
  22/01/2009
• EC decision date:
  27/05/2009

All documents

Elements recommended for inclusion in Summaries of Product Characteristics for methylphenidate-containing medicinal products authorised for the treatment of ADHD in children aged six years and above and adolescents

Adopted

Methylphenidate - Article 31 referral - Annex I, II, III, IV

Adopted

Questions and answers on the review of medicines containing methylphenidate

AdoptedReference Number: EMEA/658285/2008

Description of documents published

Please note that some of the listed documents apply only to certain procedures.

• Overview - lay-language summary of the stage of the procedure
• Notification – a letter from a Member State, the European Commission or the marketing authorisation holder requesting the initiation of the procedure
• Scientific background – further background information from the triggering Member State on the issues leading to the initiation of the procedure (if applicable)
• List of questions – questions agreed by the Committee requesting further information from the marketing authorisation holder(s) / applicant(s) to evaluate the issues identified
• Timetable for the procedure – agreed timeframe to respond to the list of questions, to assess the issues and to adopt a conclusion
• List of medicines concerned by the procedure – medicine(s) / active substance(s) concerned, and marketing authorisation holder(s) / applicant(s)
• List of questions to be addressed by the stakeholders – call for data to be submitted by stakeholders (e.g. healthcare professionals, patient organisations, individual patients) (if applicable)
• Stakeholder submission form – form to be used by stakeholders to submit data (if applicable)
• Scientific conclusions – scientific conclusions of the PRAC and/or CHMP and/or CMDh
• Assessment report – PRAC or CHMP assessment and conclusions on the issues investigated, including divergent positions (if applicable)
• Divergent positions – divergent positions of the CHMP or CMDh members for pharmacovigilance procedures (if applicable)
• Changes to the summary of product characteristics, labelling and package leaflet (amended sections or fully revised version) (if applicable)
• Condition(s) to the marketing authorisation(s) – condition(s) for the safe and effective use of the medicine(s) (if applicable)
• Condition for lifting the suspension – condition to be fulfilled for the suspension of the marketing authorisation(s) to be lifted (if applicable)
• Timetable for implementation of CMDh position – agreed timeframe to submit and finalise the variation(s) implementing the outcome of the procedure (if applicable)

Note that older documents may have different titles.